Reading this on a mobile device? Try our optimized mobile version here:

April 30, 2012
BIO has teamed up with FedEx to offer member companies discounts of up to 35% off select FedEx Express, FedEx Ground and FedEx Home Delivery services through the BIO Business Solutions cost-savings program. Learn more.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at

  Today's Top Story 
  • Why pharma acquisitions are heating up
    Patent expiration and fewer drug approvals are driving the pharmaceutical industry to consolidate, David Maris writes. To strengthen their drug portfolios, major drugmakers are either acquiring biotech firms with solid pipelines or teaming up with smaller companies in drug research and development. According to publicly available data, each major pharmaceutical firm could have more than 100 partnerships, Maris writes. Forbes (4/27) LinkedInFacebookTwitterEmail this Story
Boehringer Ingelheim is the leading biopharmaceutical contract manufacturer with 35 years of experience – and 19 commercial products. At our globally licensed facilities in Biberach (Germany), Vienna (Austria) and Fremont (USA) we offer our customers flexible modules covering the entire process chain from cell line development to fill & finish.
  Health Care & Policy 
  • Epizyme, Celgene unite to develop cancer drugs
    Celgene International and Epizyme agreed to collaborate to discover, develop and market histone methyltransferase-inhibiting treatments for genetically defined cancers. Epizyme will receive $90 million upfront and could get more than $160 million in milestone payments for each HMT inhibitor licensed by Celgene, plus royalties. Epizyme will keep U.S. rights, while Celgene will have the exclusive option to license rights in markets outside the U.S. for at least three years. Mass High Tech (Boston) (4/26), Genetic Engineering & Biotechnology News (4/26) LinkedInFacebookTwitterEmail this Story
  • Amgen to work with FDA on Xgeva
    The FDA has asked Amgen for more trial data on the use of Xgeva for slowing tumor progression to the bone in patients with advanced prostate cancer. The agency said reviewers found the drug's risks outweighed its benefits. Los Angeles Business Journal (free registration) (4/27) LinkedInFacebookTwitterEmail this Story
7 keys: Put real-world evidence into action
Life sciences organizations need to know how their therapies work in the real world once clinical trials end. And these seven key components to standardizing real-world data and analytics platforms are how they get started. Read the paper, Institutionalizing Real World Evidence.
  Company & Financial News 
  • ReNeuron gets funding for stem cell program
    ReNeuron has raised about $10 million for its stem cell research and development program. The stem cell therapy ReN001, which is based on ReNeuron's lead neural stem cell line, is being tested in patients disabled by stroke. ReNeuron's other stem cell treatments include ReN009 for peripheral arterial disease and ReN003 for diseases of the retina. (U.K.) (4/27) LinkedInFacebookTwitterEmail this Story
  Featured Content 

  Food & Agriculture 
  • Safflower high in oleic oil developed in Australia
    Australia's Commonwealth Scientific and Industrial Research Organisation, together with the Grains Research and Development Corporation, developed a variety of safflower that produces high amounts of oleic oil, which is used in food and industrial feedstocks. The CSIRO Crop Biofactories Initiative silenced genes involved in the conversion of oleic acids to polyunsaturates. Australian Life Scientist (4/27) LinkedInFacebookTwitterEmail this Story
  Hot Topics 

Top five news stories selected by BIO SmartBrief readers in the past week.

  • Results based on number of times each story was clicked by readers.
  Industrial & Environmental 
  • Senate panel approves $800M in funding for biofuels in farm bill
    The Senate Agriculture Committee endorsed a farm bill that would preserve $800 million in funding for biofuel programs that were created in the 2008 version of the legislation. The panel initially considered a bill that would cut funding for the biofuel programs, but in a voice vote it approved an amendment by Sens. Kent Conrad, D-N.D., and Dick Lugar, R-Ind., to reauthorize the programs' funding. Sen. Amy Klobuchar, D-Minn., who supported the amendment, said that "it's incredibly important to move towards the next generation of biofuels." Platts (4/26), (4/26) LinkedInFacebookTwitterEmail this Story
A sound mind in a sound body is a short but full description of a happy state in this world."
--John Locke,
British philosopher

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
A powerful website for SmartBrief readers including:
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.® Legal Information